Moderna's Flu Shot Now Has a Wall Street Backer - and a Cost Bill That Shrinks by $200 Million - ad-hoc-news.de
Article excerpt
Moderna closed its third quarter of 2026 with a profit, a raised sales outlook, and a new product approval in hand. Yet the detail that may matter most to shareholders sits further down the income statement: the company is spending far less on research than it was a year ago, and a private equity giant is now shouldering part of the development bill. Moderna posted revenue of $1.3 billion for the three months, up 29% from a year earlier. Net income came in at $162 million on a GAAP basis, a sharp reversal from the $200 million loss recorded in the third quarter of 2025. Diluted earnings per share reached $0.38. Higher international sales of COVID-19 vaccines and payments tied to government partnerships underpinned the quarter, according to Reuters. Those long-term government agreements also contributed to top-line growth. The stock responded with a 5.7% advance following the release. Management now guides toward 15%–25% revenue growth for the full year 2026, a substantial upgrade from the maximum of 10% previously held out. The company also trimmed its outlook for operating expenses by roughly $0.2 billion. Should investors sell immediately? Or is it worth buying Moderna? Research and development costs totaled $583 million in the quarter, down 27% year over year. Lower outlays for clinical trials, personnel and stock-based compensation all played a part. For the full year...
Keep reading with a free account
The rest of this article, and every signal for Moderna, is in your free account.
Extracted from this sentence
The FDA's clearance of mFLUSIVA, announced yesterday, makes it the fifth product Moderna has brought to market worldwide, according to the company.
